Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib cream MUsT study in pediatric atopic dermatitis
NCT05034822Phase 1Completed
- Sponsor
- Incyte
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib cream in atopic dermatitis (AD), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events at 61 weeks. Started Dec 2021; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05034822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034822.